222 related articles for article (PubMed ID: 21830928)
1. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
Xia HA; Ma H; Carlin BP
J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
[TBL] [Abstract][Full Text] [Related]
2. Mining pharmacovigilance data using Bayesian logistic regression with James-Stein type shrinkage estimation.
An L; Fung KY; Krewski D
J Biopharm Stat; 2010 Sep; 20(5):998-1012. PubMed ID: 20721787
[TBL] [Abstract][Full Text] [Related]
3. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
[TBL] [Abstract][Full Text] [Related]
4. Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.
Huang L; Zalkikar J; Tiwari RC
J Biopharm Stat; 2013; 23(1):178-200. PubMed ID: 23331230
[TBL] [Abstract][Full Text] [Related]
5. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
6. BayesWeb: a user-friendly platform for exploratory Bayesian analysis of safety signals from small clinical trials.
Scott JA; Hand AL; Sian LS
J Biopharm Stat; 2011 Sep; 21(5):1030-41. PubMed ID: 21830929
[TBL] [Abstract][Full Text] [Related]
7. Detecting potential safety issues in clinical trials by Bayesian screening.
Gould AL
Biom J; 2008 Oct; 50(5):837-51. PubMed ID: 18932142
[TBL] [Abstract][Full Text] [Related]
8. Extreme value modelling of laboratory safety data from clinical studies.
Southworth H; Heffernan JE
Pharm Stat; 2012; 11(5):361-6. PubMed ID: 22684727
[TBL] [Abstract][Full Text] [Related]
9. Bayesian approach for clinical trial safety data using an Ising prior.
McEvoy BW; Nandy RR; Tiwari RC
Biometrics; 2013 Sep; 69(3):661-72. PubMed ID: 23845253
[TBL] [Abstract][Full Text] [Related]
10. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting.
Ahmed I; Haramburu F; Fourrier-Réglat A; Thiessard F; Kreft-Jais C; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
Stat Med; 2009 Jun; 28(13):1774-92. PubMed ID: 19360795
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of computer-aided disproportionality analysis for post-marketing signal detection.
Lehman HP; Chen J; Gould AL; Kassekert R; Beninger PR; Carney R; Goldberg M; Goss MA; Kidos K; Sharrar RG; Shields K; Sweet A; Wiholm BE; Honig PK
Clin Pharmacol Ther; 2007 Aug; 82(2):173-80. PubMed ID: 17507922
[TBL] [Abstract][Full Text] [Related]
12. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting.
Bonangelino P; Irony T; Liang S; Li X; Mukhi V; Ruan S; Xu Y; Yang X; Wang C
J Biopharm Stat; 2011 Sep; 21(5):938-53. PubMed ID: 21830924
[TBL] [Abstract][Full Text] [Related]
13. Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study.
Van Holle L; Zeinoun Z; Bauchau V; Verstraeten T
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):603-10. PubMed ID: 22383219
[TBL] [Abstract][Full Text] [Related]
14. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
Maro JC; Brown JS
Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
[TBL] [Abstract][Full Text] [Related]
15. Signal detection in FDA AERS database using Dirichlet process.
Hu N; Huang L; Tiwari RC
Stat Med; 2015 Aug; 34(19):2725-42. PubMed ID: 25924820
[TBL] [Abstract][Full Text] [Related]
16. A shrinkage-based comparative assessment of observed-to-expected disproportionality measures.
Gipson G
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):589-96. PubMed ID: 22290739
[TBL] [Abstract][Full Text] [Related]
17. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
Odani M; Fukimbara S; Sato T
Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
[TBL] [Abstract][Full Text] [Related]
19. Data mining and statistically guided clinical review of adverse event data in clinical trials.
Southworth H; O'Connell M
J Biopharm Stat; 2009 Sep; 19(5):803-17. PubMed ID: 20183445
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.
Baker RA; Pikalov A; Tran QV; Kremenets T; Arani RB; Doraiswamy PM
Psychopharmacol Bull; 2009; 42(1):11-31. PubMed ID: 19204649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
